BioCentury | Mar 19, 2021
Deals

How Five Prime got a sweetened buyout offer from Amgen as rival suitors dropped out of bidding process

...proposed collaborations before Amgen Inc. (NASDAQ:AMGN) clinched the deal with its March 1 bid, valuing Five Prime Therapeutics...
...2 b isoformHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos Bemarituzumab (FPA144) Amgen Inc. Five Prime Therapeutics...
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...and served as CEO at RayzeBio Inc. He was also CEO and president at Five Prime Therapeutics...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

...says Fishburn.For this week’s Deal in Focus, Executive Editor Jeff Cranmer discusses the acquisition of Five Prime Therapeutics...
...surveys. For more information, please contact Eric Pierce and Josh Berlin at conferences@biocentury.com. Jeff Cranmer Amgen Inc. Five Prime Therapeutics...
BioCentury | Mar 4, 2021
Deals

Precision oncology readout becomes Five Prime’s denouement, driving $1.9B Amgen takeout

...outsized interest in precision oncology.Amgen Inc. (NASDAQ:AMGN) will pay $38 per share to acquire Five Prime Therapeutics...
...Epidermal growth factor receptor 2MUC17 (MUC3) - Mucin 17, cell surface associated Paul Bonanos Bemarituzumab (FPA144) Five Prime Therapeutics...
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...Spring Bank Pharmaceuticals Inc., which reverse-merged with F-star Therapeutics Inc. (NASDAQ:FSTX).Indapta Therapeutics Inc. hired former Five Prime Therapeutics...
BioCentury | Nov 11, 2020
Product Development

As bemarituzumab data validate FGFR2b target in gastric cancers, Five Prime shares surge after hours

...efficacy data for Five Prime’s bemarituzumab.Shares of Five Prime Therapeutics...
...Fibroblast growth factor receptor 2b isoform Lauren Martz Five Prime Therapeutics...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...cancer therapies to which Zai holds regional rights. They include FGFR2b program bemarituzumab from Five Prime Therapeutics...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...Lyndah Dreiling as SVP, clinical development. She was VP, head of clinical development at Five Prime Therapeutics...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...chair and therapeutic area head for oncology at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cancer company Five Prime Therapeutics...
...Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Cardurion Pharmaceuticals LLC Sangamo Therapeutics Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...is developing engineered hematopoietic stem cells to enable the broader use of targeted cancer immunotherapies. Prime Therapeutics LLC...
...Bioscience plc Asklepios BioPharmaceutical Inc. Gritstone Oncology Inc. Calliditas Therapeutics AB Gadeta B.V. Seres Therapeutics Inc. Dynamk Capital Polyneuron Pharmaceuticals AG Vor Biopharma Inc. Prime Therapeutics LLC Oncoceutics...
Items per page:
1 - 10 of 213
BioCentury | Mar 19, 2021
Deals

How Five Prime got a sweetened buyout offer from Amgen as rival suitors dropped out of bidding process

...proposed collaborations before Amgen Inc. (NASDAQ:AMGN) clinched the deal with its March 1 bid, valuing Five Prime Therapeutics...
...2 b isoformHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos Bemarituzumab (FPA144) Amgen Inc. Five Prime Therapeutics...
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...and served as CEO at RayzeBio Inc. He was also CEO and president at Five Prime Therapeutics...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

...says Fishburn.For this week’s Deal in Focus, Executive Editor Jeff Cranmer discusses the acquisition of Five Prime Therapeutics...
...surveys. For more information, please contact Eric Pierce and Josh Berlin at conferences@biocentury.com. Jeff Cranmer Amgen Inc. Five Prime Therapeutics...
BioCentury | Mar 4, 2021
Deals

Precision oncology readout becomes Five Prime’s denouement, driving $1.9B Amgen takeout

...outsized interest in precision oncology.Amgen Inc. (NASDAQ:AMGN) will pay $38 per share to acquire Five Prime Therapeutics...
...Epidermal growth factor receptor 2MUC17 (MUC3) - Mucin 17, cell surface associated Paul Bonanos Bemarituzumab (FPA144) Five Prime Therapeutics...
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...Spring Bank Pharmaceuticals Inc., which reverse-merged with F-star Therapeutics Inc. (NASDAQ:FSTX).Indapta Therapeutics Inc. hired former Five Prime Therapeutics...
BioCentury | Nov 11, 2020
Product Development

As bemarituzumab data validate FGFR2b target in gastric cancers, Five Prime shares surge after hours

...efficacy data for Five Prime’s bemarituzumab.Shares of Five Prime Therapeutics...
...Fibroblast growth factor receptor 2b isoform Lauren Martz Five Prime Therapeutics...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...cancer therapies to which Zai holds regional rights. They include FGFR2b program bemarituzumab from Five Prime Therapeutics...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...Lyndah Dreiling as SVP, clinical development. She was VP, head of clinical development at Five Prime Therapeutics...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...chair and therapeutic area head for oncology at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cancer company Five Prime Therapeutics...
...Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Cardurion Pharmaceuticals LLC Sangamo Therapeutics Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...is developing engineered hematopoietic stem cells to enable the broader use of targeted cancer immunotherapies. Prime Therapeutics LLC...
...Bioscience plc Asklepios BioPharmaceutical Inc. Gritstone Oncology Inc. Calliditas Therapeutics AB Gadeta B.V. Seres Therapeutics Inc. Dynamk Capital Polyneuron Pharmaceuticals AG Vor Biopharma Inc. Prime Therapeutics LLC Oncoceutics...
Items per page:
1 - 10 of 213